A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

BACKGROUND: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model. OBJECTIVE: To establish clinical feasibility, a phase Ib dose-escalation trial investigating safety and pharmacokinetics of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wise-Draper, Trisha M., Moorthy, Ganesh, Salkeni, Mohamad A., Karim, Nagla Abdel, Thomas, Hala Elnakat, Mercer, Carol A., Beg, M. Shalaan, O’Gara, Sue, Olowokure, Olugbenga, Fathallah, Hassana, Kozma, Sara C., Thomas, George, Rixe, Olivier, Desai, Pankaj, Morris, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447332/
https://www.ncbi.nlm.nih.gov/pubmed/28357727
http://dx.doi.org/10.1007/s11523-017-0482-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447332/
https://www.ncbi.nlm.nih.gov/pubmed/28357727
http://dx.doi.org/10.1007/s11523-017-0482-9

Ejemplares similares